Abstract
BRAF mutations can be classified into 3 groups based on molecular characteristics. Targeted therapies exist for Class 1 (V600) BRAF mutations, but effective treatments have not been established for non-V600 Class 2 or 3 BRAF mutations. Several clinical trials are enrolling patients with Class 2/3 mutations, but many barriers to enrollment persist. We sought to determine whether BRAF mutation class varied according to key demographic differences in cancer populations.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
